Drug · CHEMBL549
CITALOPRAM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CITALOPRAM. Drugs and targets, record CHEMBL549. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL549
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | Serotonin transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6532 |
Source ChEMBL
Diseases45
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 45Source Open Targets
See all 45 diseasesTrials173
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01473381 | Safety and Efficacy of Vilazodone in Major Depressive Disorder | Phase 4 | 1,162 | 2014-08-08 | citalopram | Its name | ClinicalTrials.gov |
| NCT00666757 | A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression | Phase 4 | 750 | 2010-06-15 | citalopram | Its name | ClinicalTrials.gov |
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | 635 | 2021-07-02 | citalopram | Its name | ClinicalTrials.gov | |
| NCT01312922 | Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD) | Phase 3 | 555 | 2022-04-07 | citalopram | Its name | ClinicalTrials.gov |
| NCT04476030 | A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | Phase 3 | 440 | 2023-11-07 | citalopram | Its name | ClinicalTrials.gov |
| NCT01179568 | A Study of Medication With or Without Psychotherapy for Complicated Grief | Phase 2 | 395 | 2017-01-24 | citalopram | Its name | ClinicalTrials.gov |
| NCT00898807 | Citalopram for Agitation in Alzheimer's Disease | Phase 3 | 186 | 2014-06-27 | citalopram | Its name | ClinicalTrials.gov |
| NCT00602290 | Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression | Phase 4 | 181 | 2014-09-01 | citalopram | Its name | ClinicalTrials.gov |
| NCT01032018 | Comparison of Depression Interventions After Acute Coronary Syndrome | Phase 1/2 | 150 | 2014-08-12 | citalopram | Its name | ClinicalTrials.gov |
| NCT00562861 | Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram | Phase 2/3 | 119 | 2017-02-13 | citalopram | Its name | ClinicalTrials.gov |
1 to 10 of 173
See all 173 trialsComparisons in its trials27
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alcohol Abuse or Dependence vs Major Depression Only: serious adverse events | 8 of 138 | 23 of 536 | 674 | NCT00369746 | Trial comparisons |
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Placebo + Assigned ADT vs SAGE-217 + Assigned ADT: deaths from any cause | 0 of 220 | 0 of 220 | 440 | NCT04476030 | Trial comparisons |
| Placebo + Assigned ADT vs SAGE-217 + Assigned ADT: serious adverse events | 0 of 218 | 2 of 212 | 430 | NCT04476030 | Trial comparisons |
| Citalopram and Psychosocial Intervention vs Placebo and Psychosocial Intervention: serious adverse events | 8 of 94 | 7 of 92 | 186 | NCT00898807 | Trial comparisons |
| Referred Care vs Stepped Care: serious adverse events | 8 of 77 | 7 of 73 | 150 | NCT01032018 | Trial comparisons |
| Citalopram vs Placebo: serious adverse events | 1 of 60 | 0 of 59 | 119 | NCT00562861 | Trial comparisons |
| Citalopram vs Placebo: serious adverse events | 5 of 49 | 4 of 46 | 95 | NCT01041274 | Trial comparisons |
| Citalopram vs Placebo: serious adverse events | 0 of 40 | 0 of 41 | 81 | NCT00962039 | Trial comparisons |
1 to 10 of 27
See all 27 comparisons in its trialsPapers from its trials274
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials23
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Go/No-Go Task | 3 | 1 | ConductCognition |
| Stroop Color-Word Test | 3 | 2 | ConductCognition |
| Symbol Coding | 3 | 1 | ConductCognition |
| Trail Making Test A | 3 | 0 | ConductCognition |
| Trail Making Test B | 3 | 1 | ConductCognition |
| Block Copy Test | 1 | 0 | ConductCognition |
| Card Sorting Test (Berg) | 1 | 0 | ConductCognition |
| Category Fluency | 1 | 1 | ConductCognition |
| Dot-Probe Task | 1 | 0 | ConductCognition |
| Emotion Regulation Task | 1 | 0 | ConductCognition |
1 to 10 of 23
See all 23 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL549
GET https://conductscience.org/api/drugs/v1/CHEMBL549/diseases?page=2